Ophthalmic research specialists combine preclinical efforts to accelerate lead progress.
Pharmaceutical CRO, Calvert Labs (NC, USA), and EyeCro (OK, USA) have recently announced their strategic partnership over preclinical drug development activities. The enterprise is aiming to aid the transition of leads from the discovery phase into GLP IND-enabling studies.
EyeCRO, a specialist in ophthalmic preclinical efficacy studies, utilizes animal models in their drug-development approach such as, laser induce choroidal neovascularization, streptozotocin-induced diabetes, and intraocular ischemia/reperfusion injury. Rafal Farjo, Chief Operating Officer of EyeCRO, said of the collaboration, “We are proud to be aligned with the prestigious team at Calvert Labs. Together, we can provide superior preclinical services to support ophthalmic drug discovery and development programs from proof-of-concept to completion of all IND-enabling studies.”
According to Russ C. McLauchlan, Chairman and Chief Executive Officer of Calvert Holdings, Inc., “The Calvert Peferred Partner Network creates a formal, collaborative support network to better serve the specialized needs of our clients, many of which rely on multiple partners to achieve program goals and objectives.” As part of the network, Calvert Labs will provide a range of lead optimization and preclinical services, with aims to help EyeCRO achieve milestones more effectively than previously possible.